RT Journal Article SR Electronic T1 Multidisciplinary transcatheter aortic valve replacement heart team programme improves mortality in aortic stenosis JF Open Heart JO Open Heart FD British Cardiovascular Society SP e000983 DO 10.1136/openhrt-2018-000983 VO 6 IS 2 A1 Dylan R Jones A1 Derek P Chew A1 Matthew J Horsfall A1 Anthony Ming-Yu Chuang A1 Ajay R Sinhal A1 Majo X Joseph A1 Robert A Baker A1 Jayme S Bennetts A1 Joseph B Selvanayagam A1 Sam J Lehman YR 2019 UL http://openheart.bmj.com/content/6/2/e000983.abstract AB Objectives To analyse the effect of the implementation of a transcatheter aortic valve replacement (TAVR) and multidisciplinary heart team programme on mortality in severe aortic stenosis (AS).Methods A retrospective, observational cohort study was performed using the echocardiography, cardiothoracic surgery and TAVR databases between 1 January 2006 and 31 December 2016. Outcomes were compared between the pre- and post-TAVR programme eras in a tertiary referral centre providing transcatheter and surgical interventions for AS.All-cause mortality within 5 years from diagnosis was determined for 3399 patients with echocardiographically defined severe AS.Results Of 3399 patients, there were 210 deaths (6.2%) at 30 days and 1614 deaths (47.5%) at 5 years.Overall, patients diagnosed in the post-TAVR programme era were older, with a lower ejection fraction and more severe AS, but were less comorbid.Among 705 patients undergoing intervention, those in the post-TAVR programme era were older, with a lower ejection fraction and more severe AS but no significant differences in comorbidities.Using an inverse probability weighted cohort and a Cox proportional hazards model, a significant mortality benefit was noted between eras alone (HR=0.86, 95% CI 0.77 to 0.97, p=0.015). When matching for age, comorbidities and valve severity, this benefit was more evident (HR=0.82, 95% CI 0.73 to 0.92, p=0.001).After adjusting for the presence of aortic valve intervention, a significant benefit persisted (HR=0.84, 95% CI 0.75 to 0.95, p=0.005).Conclusion The implementation of a TAVR programme is associated with a mortality benefit in the population with severe AS, independent of the expansion of access to intervention.